Actelion to discuss its specialty immunology pipeline compounds
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion to discuss its specialty immunology pipeline compounds
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Dear member of the investment community
Actelion has announced that it is accelerating its clinical development efforts
in the field of immunological disorders. An investor conference call & webcast
will be held at 13.00 hrs, CEST to offer the opportunity to discuss the rational
for this strategic decision.
Date/Time:
16 April 2015 13.00 hrs - 14.00 hrs Basel (CEST)
12.00 hrs - 13.00 hrs UK (BST)
07.00 a.m. - 08.00 a.m. US (EDT)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before
the conference is due to start.
Dial: Europe: +41 (0) 44 580 00 77
UK: +44 (0) 203 367 94 59
US: +1 866 907 59 28
Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast Access:
Webcast participants should visit the Actelion website http://www.actelion.com
10-15 minutes before the conference is due to start.
Participant's mode:
Listen-Only
Webcast Replay:
The archived Investor Webcast will be available for replay through
http://www.actelion.com/ approximately 60 minutes after the call has ended.
Invitation PDF:
http://hugin.info/131801/R/1911453/682012.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1911453]
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2015 - 07:05 Uhr
Sprache: Deutsch
News-ID 386162
Anzahl Zeichen: 2490
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 151 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion to discuss its specialty immunology pipeline compounds"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
